Clinical Trial Search

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14

Primary: Objective Response Rate — .85 proportion of patients

Primary: Overall Response Rate — 40; 55; 29 percentage of patients

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants

Primary: Optimal Biologic Dose of MEDI-551 for Part A — 12 mg/Kg

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 29; 49; 11; 15 participants

Primary: Overall Response Rate — 81.8 Percentage

Primary: Part 1 and Part 2: Number of Participants With Adverse Events — 3; 4; 5; 274 Participants

Primary: Total Number of Adverse Events. — 2 Adverse events

Primary: Progression-free Survival at 2 Years — 15 Participants

Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…

Primary: Number of Participants With Toxicity — 8 participants

Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants

Primary: ORR (Overall Response Rate) — 46 Percentage of Participants

Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation — 3; 9; 5; 19 Participants

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants

Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg

Primary: Number of Participants (Par.) With Response as Assessed by the Investigator — 31 participants

Primary: ORR — 88; 81 percentage of patients

Primary: Overall Rate of Response (ORR) in Participants Receiving Protocol Therapy. — 87.5 percentage of participants

Primary: Maximum Tolerated Dose (MTD) of MEDI-551 — NA; NA mg/kg

Primary: Efficacy: Complete Response Rate (CRR) — 9.5 percentage of patients

Primary: Overall Response — 3; 3; 3; 2 Participants

Primary: Phase I: Dose Limiting Toxicities (DLT) Rate — 3; 5; 0; 1 Participants

Primary: Overall Response Rate as Assessed According to the"Revised Response Criteria for Malignant Lymphoma" (Cheson 2007). — 5; 2; 7; 1 Participants

Primary: Number of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR) — 19; 8 participants